{
  "ticker": "LLY",
  "timestamp": "2025-12-01T08:32:16.373229",
  "analysis_date": "2025-06-30",
  "historical_mode": true,
  "summary": {
    "recommendations": {
      "technical": "HOLD",
      "news": "HOLD",
      "fundamental": "HOLD",
      "macro": "HOLD"
    },
    "valid_recommendations": {
      "technical": "HOLD",
      "news": "HOLD",
      "fundamental": "HOLD",
      "macro": "HOLD"
    },
    "confidence_levels": {
      "technical": "Low",
      "news": "Medium",
      "fundamental": "Low",
      "macro": "Low"
    },
    "bull_signal_count": 26,
    "bear_signal_count": 13,
    "bull_rec_count": 0,
    "bear_rec_count": 0,
    "hold_rec_count": 4,
    "undetermined_count": 0,
    "analyst_count": 4,
    "valid_analyst_count": 4,
    "net_sentiment": "NEUTRAL"
  },
  "analyst_summaries": {
    "technical": "TECHNICAL: Downtrend confirmed, RSI 14 \u2192 HOLD (Low)",
    "news": "NEWS: Bullish sentiment (83 articles) \u2192 HOLD (Medium)",
    "fundamental": "FUNDAMENTAL: Mixed fundamentals \u2192 HOLD (Low)",
    "macro": "MACRO: Mixed macro \u2192 HOLD (Low)"
  },
  "full_analyst_reports": {
    "technical": "[TECHNICAL] *** HISTORICAL MODE: Analyzing as of 2025-06-30 ***\n\n======================================================================\nTECHNICAL ANALYSIS: LLY\nAnalysis Period: 7 days\n*** HISTORICAL MODE: As of 2025-06-30 ***\nTimestamp: 2025-12-01 08:30:48\n======================================================================\n\n[TECHNICAL] Fetching 7-day price data for LLY...\n[TECHNICAL] \u2713 Historical: 50 days ending 2025-06-30\n[TECHNICAL]   Date range: 2025-04-17 to 2025-06-30\n[TECHNICAL] \u2713 Retrieved 50 days of data\n[TECHNICAL] Calculating technical indicators...\n[TECHNICAL] \u2713 Indicators calculated\n[TECHNICAL] Identifying support/resistance levels...\n[TECHNICAL] \u2713 Support: $728.03, Resistance: $821.98\n[TECHNICAL] Formatting technical summary...\n[TECHNICAL] Generating analysis with gpt-4o-mini...\n[TECHNICAL] \u274c LLM error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o-mini in organization org-KtddXWX7pT8yz52FN9uLjN7j on requests per day (RPD): Limit 10000, Used 10000, Requested 1. Please try again in 8.64s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'requests', 'param': None, 'code': 'rate_limit_exceeded'}}\n[TECHNICAL] Creating fallback analysis...\n\n[TECHNICAL] \u2713 Analysis complete in 18.72s\n======================================================================\n\n## Technical Analysis\n*Generated using fallback analysis (LLM unavailable)*\n\n\n**\u26a0\ufe0f HISTORICAL ANALYSIS AS OF 2025-06-30 \u26a0\ufe0f**\nAll data below is historical, ending on 2025-06-30.\nDo NOT reference any price movements or events after this date.\n\n# Technical Analysis Data for LLY\n\n**Analysis Period:** 7 days (Data: 50 days available)\n**Date:** 2025-06-30\n\n## Price Action\n- **Current Price:** $776.68\n- **Period Change:** +2.20%\n- **Day's Range:** $771.17 - $782.13\n- **Volume:** 3,041,500\n- **Volume Assessment:** Normal levels\n\n## Momentum Indicators\n- **RSI(14):** 51.8 \u2192 Neutral zone\n- **MACD:** 3.091 | Signal: 3.353 | Histogram: -0.262\n  \u2192 Bearish momentum \u26a0\ufe0f\n- **Stochastic:** %K=34.5, %D=40.0\n\n## Moving Average Analysis\n- **SMA_5:** $781.23 (Below \u26a0\ufe0f)\n- **EMA_10:** $780.13 (Below \u26a0\ufe0f)\n- **SMA_20:** $780.03 (Below \u26a0\ufe0f)\n- **SMA_50:** $778.97 (Below \u26a0\ufe0f)\n\n**Trend:** Strong downtrend (price below all MAs) \u26a0\ufe0f\n\n## Volatility & Range\n- **Bollinger Bands:** $738.76 < $776.68 < $821.31\n  \u2192 Middle range (46% position)\n- **ATR:** $20.39 (2.63% of price)\n  \u2192 Normal volatility\n\n## Support & Resistance\n- **Key Resistance:** $821.98\n- **Secondary Resistance:** $821.98\n- **Key Support:** $728.03\n- **Secondary Support:** $738.75\n\n- **Distance to Resistance:** +5.8%\n- **Distance to Support:** +6.7%\n\n## Potential Trade Setup\n- **Setup Type:** SHORT\n- **Entry:** $776.68\n- **Stop Loss:** $807.27 (Risk: $30.58)\n- **Target:** $728.03 (Reward: $48.65)\n- **Risk/Reward Ratio:** 1.59:1\n  \u2192 Acceptable risk/reward\n\n\n---\n\n## Automated Assessment\n\n**Signals Detected:** 0 bullish, 1 bearish\n**Reasoning:** Mixed or weak signals\n\nRECOMMENDATION: HOLD - Confidence: Low\n\n",
    "news": "[NEWS] *** HISTORICAL MODE: Analyzing as of 2025-06-30 ***\n\n======================================================================\nNEWS & SENTIMENT ANALYSIS: LLY\n*** HISTORICAL MODE: As of 2025-06-30 ***\nPeriod: Last 7 days | Sources: ['yahoo', 'finnhub']\nTimestamp: 2025-12-01 08:31:09\n======================================================================\n\n[NEWS] \ud83d\udd27 Fetching Yahoo Finance news...\n[NEWS] \u26a0\ufe0f Yahoo Finance has limited historical news support\n[NEWS] \u2713 Yahoo Finance: 0 articles\n[NEWS] \ud83d\udd27 Fetching Finnhub news...\n[NEWS] Finnhub: Fetching news from 2025-06-23 to 2025-06-30\n[NEWS] \u2713 Finnhub: 83 articles\n[NEWS] \ud83d\udccb Enhancing 83 articles with background context\n[NEWS] \u26a0\ufe0f Date 2025-06-30 is past LLM knowledge cutoff (2024-01-01)\n[NEWS] \u26a0\ufe0f Skipping LLM context to prevent hallucination\n[NEWS] Analyzing with gpt-4o-mini...\n[NEWS] \u2713 Analysis complete (2388 chars)\n\n[NEWS] \u2713 Analysis complete in 10.50s\n======================================================================\n\n# News & Sentiment Analysis: LLY\n**\u26a0\ufe0f HISTORICAL ANALYSIS AS OF 2025-06-30 \u26a0\ufe0f**\n**Analysis Period:** Last 7 Days\n**Date:** 2025-12-01 08:31\n\n======================================================================\n\n## Yahoo Finance News (7 Days before 2025-06-30)\n\nNo news found in the specified period\n(Historical mode: news before 2025-06-30)\n## Finnhub News (2025-06-23 to 2025-06-30)\n\n**Found 83 articles**\n\n1. **FDA Approves Updated Label For Eli Lilly and Company (LLY)\u2019s Amyvid To Support Alzheimer\u2019s Diagnosis**\n   - Source: Yahoo\n   - Published: today\n   - Eli Lilly and Company (NYSE:LLY) is among the Goldman Sachs Stock Portfolio: 10 Large-Cap Stocks To Buy. On June 25, the company announced that the FD...\n\n2. **Can Protagonist Take On Eli Lilly's Next-Generation Obesity Treatment?**\n   - Source: Yahoo\n   - Published: today\n   - Protagonist Therapeutics is taking aim directly at Eli Lilly's obesity treatment with a newly announced drug that uses the same mechanism....\n\n3. **Eli Lilly (LLY) Faces Bearish Options Flow, But Probabilities Tell a Different Story**\n   - Source: Yahoo\n   - Published: today\n   - Options traders leaned bearish on LLY stock, but market demand data reveals conditional odds that may support near-term upside....\n\n4. **Will CVS Health's Formulary Move Boost Its Weight Management Program? (Revised)**\n   - Source: Yahoo\n   - Published: today\n   - CVS adds Wegovy to its top formularies and bolsters its Weight Management program, aiming to expand access while cutting costs....\n\n5. **RBC says Lilly could blaze trail and Biogen could pull ahead in Alzheimer\u2019s market**\n   - Source: Yahoo\n   - Published: today\n   - Investing.com -- RBC Capital Markets analysts believe Eli Lilly\u2019s upcoming TRAILBLAZER-3 trial data on Kisunla could unlock a vast, largely untapped s...\n\n6. **Wall Street Breakfast Podcast: UK Cars, Planes Get U.S. Break**\n   - Source: SeekingAlpha\n   - Published: today\n\n7. **Tracking Lone Pine Capital Portfolio - Q1 2025 Update**\n   - Source: SeekingAlpha\n   - Published: today\n   - Discover Lone Pine Capital's Q1 2025 investment strategy: new stakes, major increases, and reductions....\n\n8. **Calamos Long/Short Equity & Dynamic Income Trust Q1 2025 Commentary**\n   - Source: SeekingAlpha\n   - Published: today\n   - For the quarter ending March 31, 2025, Calamos Long/Short Equity & Dynamic Income Trust\u00e2\u0080\u0099s total return was 1.69% on NAV and 6.82% on market price. R...\n\n\n======================================================================\n\n## News & Sentiment Summary\nEli Lilly (LLY) is currently experiencing a mix of bullish and bearish sentiments due to recent FDA approvals and competitive pressures in the obesity treatment market. While the approval of Amyvid for Alzheimer's diagnosis is a positive development, concerns about competition from Protagonist Therapeutics and bearish options flow indicate caution among investors.\n\n## Key Headlines\n1. **FDA Approves Updated Label For Eli Lilly\u2019s Amyvid**  \n   - Impact Assessment: High. This approval supports Eli Lilly's standing in the Alzheimer's market, potentially increasing revenues.\n\n2. **Protagonist Therapeutics Challenges Eli Lilly's Obesity Treatment**  \n   - Impact Assessment: Medium. The introduction of a competing drug poses a threat to LLY's market share in a lucrative segment.\n\n3. **Bearish Options Flow for LLY**  \n   - Impact Assessment: Medium. The bearish sentiment in options trading suggests some investors are hedging against potential declines, though market data indicates possible upside.\n\n4. **RBC Analysts See Potential in LLY\u2019s Alzheimer\u2019s Treatment**  \n   - Impact Assessment: High. Positive outlook from analysts on the upcoming TRAILBLAZER-3 trial data could drive interest and investment in LLY.\n\n5. **CVS Health Adds Wegovy to Formulary**  \n   - Impact Assessment: Medium. This move may enhance competition in the weight management sector, impacting LLY\u2019s sales in obesity treatments.\n\n## Sentiment Assessment\n- **Overall Sentiment:** Mixed (Bullish on FDA approval; Bearish on competitive threats)\n- **Sentiment Trend:** Stable\n- **News Volume:** High\n\n## Catalysts Identified\n**Bullish Catalysts:** \n- FDA approval of Amyvid for Alzheimer's diagnosis\n- Positive analyst sentiment regarding upcoming trial data\n\n**Bearish Catalysts:**\n- Competitive challenge from Protagonist Therapeutics' obesity treatment\n- Bearish options trading indicating caution in the market\n\n**Upcoming Events:**\n- Release of TRAILBLAZER-3 trial data (date not specified)\n\n## Trading Implications\nInvestors should consider the mixed signals from recent developments. The FDA approval is a strong bullish indicator; however, competition in the obesity treatment market and the bearish options flow suggest caution is warranted. The upcoming trial data will be critical in determining the stock's near-term direction.\n\nRECOMMENDATION: HOLD - Confidence: Medium\n",
    "fundamental": "[FUNDAMENTALS] *** HISTORICAL MODE: Analyzing as of 2025-06-30 ***\n\n======================================================================\nFUNDAMENTAL ANALYSIS: LLY\n*** HISTORICAL MODE: As of 2025-06-30 ***\nTimestamp: 2025-12-01 08:31:22\n======================================================================\n\n[FUNDAMENTALS] Fetching comprehensive data for LLY...\n[FUNDAMENTALS] \u2713 Comprehensive data retrieved\n[FUNDAMENTALS] Calculating historical metrics for 2025-06-30...\n[FUNDAMENTALS] \u2713 Historical metrics calculated: 4\n[FUNDAMENTALS]   - Price: $776.68\n[FUNDAMENTALS]   - P/E: 50.37\n[FUNDAMENTALS]   - P/B: 38.04\n[FUNDAMENTALS]   - Current Ratio: 1.28\n[FUNDAMENTALS] Analyzing earnings history...\n[FUNDAMENTALS] Filtering earnings to before 2025-06-30\n[FUNDAMENTALS] \u2713 Earnings analysis complete (3/4 beats)\n[FUNDAMENTALS] Fetching SEC 10-K filing data...\n[FUNDAMENTALS] Generating analysis with gpt-4o-mini...\n[FUNDAMENTALS] \u274c LLM error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o-mini in organization org-KtddXWX7pT8yz52FN9uLjN7j on requests per day (RPD): Limit 10000, Used 10000, Requested 1. Please try again in 8.64s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'requests', 'param': None, 'code': 'rate_limit_exceeded'}}\n\n[FUNDAMENTALS] \u2713 Analysis complete in 19.58s\n======================================================================\n\n## Fundamental Analysis Summary\n*Generated using fallback analysis (LLM unavailable)*\n\n\n**\u26a0\ufe0f HISTORICAL ANALYSIS AS OF 2025-06-30 \u26a0\ufe0f**\nMetrics marked \"N/A\" could not be calculated historically - ignore them in your analysis.\nOnly analyze metrics with actual values.\n\n# Fundamental Data for LLY\n\n## Company Information\n- **Name:** Eli Lilly and Company\n- **Sector:** Healthcare\n- **Industry:** Drug Manufacturers - General\n\n## Current Price\n- **Price:** $776.68\n- **52-Week High:** $1111.99\n- **52-Week Low:** $623.78\n\n## Valuation Metrics\n- **Market Cap:** $964.11B\n- **Enterprise Value:** $995.68B\n- **Trailing P/E:** 50.37\n- **Forward P/E:** N/A (historical - forward-looking)\n- **PEG Ratio:** N/A (historical)\n- **Price/Book:** 38.04\n- **Price/Sales:** 16.23\n- **EV/Revenue:** 16.76\n- **EV/EBITDA:** 34.66\n\n## Growth Metrics\n- **Revenue Growth:** 53.9%\n- **Earnings Growth:** 480.4%\n- **Quarterly Revenue Growth:** N/A\n- **Quarterly Earnings Growth:** N/A\n\n## Profitability\n- **Profit Margin:** 31.0%\n- **Operating Margin:** 48.3%\n- **Gross Margin:** 83.0%\n- **ROE:** 96.5%\n- **ROA:** 17.6%\n\n## Financial Health\n- **Current Ratio:** 1.28\n- **Quick Ratio:** 0.72\n- **Debt/Equity:** 178.52\n- **Total Cash:** $9.91B\n- **Total Debt:** $42.58B\n- **Free Cash Flow:** $1.40B\n\n## Analyst Opinions\n- **Recommendation:** BUY\n- **Number of Analysts:** 27\n- **Target (Mean):** $1024.00\n- **Target (High):** $1500.00\n- **Target (Low):** $770.00\n- **Implied Upside:** -4.8%\n\n## Earnings History (Last 4 Quarters)\n- Unknown: Actual $5.32 vs Est $5.07 (+5.0%) \u2713 Beat\n- Unknown: Actual $3.34 vs Est $3.54 (-5.7%) \u2717 Miss\n- Unknown: Actual $6.31 vs Est $5.59 (+12.9%) \u2713 Beat\n- Unknown: Actual $7.02 vs Est $5.89 (+19.2%) \u2713 Beat\n\n**Summary:** Beat Rate: 75%, Trend: Declining, Quality: Strong\n\n\n\nRECOMMENDATION: HOLD - Confidence: Low\n\n",
    "macro": "[MACRO] *** HISTORICAL MODE: Analyzing as of 2025-06-30 ***\n\n======================================================================\nMACRO ECONOMIC ANALYSIS\nPeriod: 7 days | Sector: All\n*** HISTORICAL MODE: As of 2025-06-30 ***\nTimestamp: 2025-12-01 08:31:44\n======================================================================\n\n[MACRO] Starting iterative analysis...\n[MACRO] Iteration 1/10\n[MACRO] \ud83d\udd27 Executing: get_market_indicators\n[MACRO] \ud83d\udd27 Tool: get_market_indicators (days=7)\n[MACRO] \u2713 Fetched 6/6 indicators\n[MACRO] \ud83d\udd27 Executing: get_sector_performance\n[MACRO] \ud83d\udd27 Tool: get_sector_performance (days=7)\n[MACRO] \u2713 Analyzed 9/9 sectors\n[MACRO] \ud83d\udd27 Executing: get_economic_indicators\n[MACRO] \ud83d\udd27 Tool: get_economic_indicators (days=7)\n[MACRO] \u2713 Economic indicators retrieved\n[MACRO] \ud83d\udd27 Executing: get_market_breadth\n[MACRO] \ud83d\udd27 Tool: get_market_breadth (days=7)\n[MACRO] \u2713 Breadth analysis complete\n[MACRO] Iteration 2/10\n[MACRO] \u274c Error in iterative analysis: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o-mini in organization org-KtddXWX7pT8yz52FN9uLjN7j on requests per day (RPD): Limit 10000, Used 10000, Requested 1. Please try again in 8.64s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'requests', 'param': None, 'code': 'rate_limit_exceeded'}}\n\n[MACRO] \u2713 Complete in 31.22s\n======================================================================\n\n# Macro Analysis (Partial)\n*Analysis Period: 7 days*\n**\u26a0\ufe0f HISTORICAL ANALYSIS AS OF 2025-06-30**\n*Successful Tools: 4, Failed: 0*\n\nRaw data gathered successfully:\n\nTools executed: get_market_indicators, get_sector_performance, get_economic_indicators, get_market_breadth\n\nRECOMMENDATION: NEUTRAL - Confidence: Low (Partial data)\n\n"
  },
  "bull_evidence": [
    {
      "source": "technical",
      "signal": "[TECHNICAL] \u2713 Support: $728",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "technical",
      "signal": "', 'type': 'requests', 'param': None, 'code': 'rate_limit_exceeded'}}",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "technical",
      "signal": "## Momentum Indicators",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "technical",
      "signal": "**Trend:** Strong downtrend (price below all MAs) \u26a0\ufe0f",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "technical",
      "signal": "- **Key Support:** $728",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "technical",
      "signal": "- **Secondary Support:** $738",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "technical",
      "signal": "- **Distance to Support:** +6",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "news",
      "signal": "- Options traders leaned bearish on LLY stock, but market demand data reveals conditional odds that may support near-term upside",
      "strength": 2,
      "keywords_matched": 2
    },
    {
      "source": "news",
      "signal": "The FDA approval is a strong bullish indicator; however, competition in the obesity treatment market and the bearish options flow suggest caution is warranted",
      "strength": 2,
      "keywords_matched": 2
    },
    {
      "source": "news",
      "signal": "[NEWS] \u26a0\ufe0f Yahoo Finance has limited historical news support",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "news",
      "signal": "**FDA Approves Updated Label For Eli Lilly and Company (LLY)\u2019s Amyvid To Support Alzheimer\u2019s Diagnosis**",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "news",
      "signal": "- Eli Lilly and Company (NYSE:LLY) is among the Goldman Sachs Stock Portfolio: 10 Large-Cap Stocks To Buy",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "news",
      "signal": "This approval supports Eli Lilly's standing in the Alzheimer's market, potentially increasing revenues",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "news",
      "signal": "Positive outlook from analysts on the upcoming TRAILBLAZER-3 trial data could drive interest and investment in LLY",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "news",
      "signal": "**Bullish Catalysts:**",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "news",
      "signal": "- Positive analyst sentiment regarding upcoming trial data",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "fundamental",
      "signal": "**Summary:** Beat Rate: 75%, Trend: Declining, Quality: Strong",
      "strength": 2,
      "keywords_matched": 2
    },
    {
      "source": "fundamental",
      "signal": "[FUNDAMENTALS] \u2713 Earnings analysis complete (3/4 beats)",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "fundamental",
      "signal": "', 'type': 'requests', 'param': None, 'code': 'rate_limit_exceeded'}}",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "fundamental",
      "signal": "- **Revenue Growth:** 53",
      "strength": 1,
      "keywords_matched": 1
    }
  ],
  "bear_evidence": [
    {
      "source": "technical",
      "signal": "03, Resistance: $821",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "technical",
      "signal": "- **Key Resistance:** $821",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "technical",
      "signal": "- **Secondary Resistance:** $821",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "technical",
      "signal": "- **Distance to Resistance:** +5",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "technical",
      "signal": "- **Risk/Reward Ratio:** 1",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "technical",
      "signal": "\u2192 Acceptable risk/reward",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "technical",
      "signal": "**Reasoning:** Mixed or weak signals",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "news",
      "signal": "While the approval of Amyvid for Alzheimer's diagnosis is a positive development, concerns about competition from Protagonist Therapeutics and bearish options flow indicate caution among investors",
      "strength": 2,
      "keywords_matched": 2
    },
    {
      "source": "news",
      "signal": "The bearish sentiment in options trading suggests some investors are hedging against potential declines, though market data indicates possible upside",
      "strength": 2,
      "keywords_matched": 2
    },
    {
      "source": "news",
      "signal": "**Eli Lilly (LLY) Faces Bearish Options Flow, But Probabilities Tell a Different Story**",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "news",
      "signal": "**Bearish Options Flow for LLY**",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "news",
      "signal": "**Bearish Catalysts:**",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "news",
      "signal": "- Bearish options trading indicating caution in the market",
      "strength": 1,
      "keywords_matched": 1
    }
  ],
  "key_conflicts": [],
  "consensus_points": [
    {
      "type": "strong_consensus",
      "recommendation": "HOLD",
      "count": 4,
      "description": "Strong consensus: 4/4 analysts say HOLD"
    }
  ],
  "research_priorities": [
    {
      "priority": "URGENT",
      "focus": "time_sensitive_event",
      "description": "Upcoming catalyst detected",
      "signal": "Positive outlook from analysts on the upcoming TRAILBLAZER-3 trial data could drive interest and investment in LLY",
      "source": "news",
      "action": "Research before event occurs"
    }
  ],
  "analyst_reports_summary": {
    "technical": {
      "recommendation": "HOLD",
      "confidence": "Low",
      "report_length": 2996,
      "has_data": true,
      "completed_successfully": true
    },
    "news": {
      "recommendation": "HOLD",
      "confidence": "Medium",
      "report_length": 5880,
      "has_data": true,
      "completed_successfully": true
    },
    "fundamental": {
      "recommendation": "HOLD",
      "confidence": "Low",
      "report_length": 3232,
      "has_data": true,
      "completed_successfully": true
    },
    "macro": {
      "recommendation": "HOLD",
      "confidence": "Low",
      "report_length": 1737,
      "has_data": true,
      "completed_successfully": true
    }
  },
  "data_quality": {
    "status": "COMPLETE",
    "total_analysts": 4,
    "valid_analysts": 4,
    "failed_analysts": 0,
    "failed_list": [],
    "note": null
  },
  "llm_synthesis": "Synthesis error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o-mini in organization org-KtddXWX7pT8yz52FN9uLjN7j on requests per day (RPD): Limit 10000, Used 10000, Requested 1. Please try again in 8.64s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'requests', 'param': None, 'code': 'rate_limit_exceeded'}}",
  "synthesis_direction": "UNDETERMINED",
  "synthesis_confidence": "N/A"
}